Venous and Arterial Endothelial Cells from Human Umbilical Cords: Potential Cell Sources for Cardiovascular Research

Skadi Lau 1, Manfred Gossen 1, Andreas Lendlein 1,2,* and Friedrich Jung 1,*

1 Institute of Active Polymers and Berlin-Brandenburg Center for Regenerative Therapies, Helmholtz-Zentrum Geesthacht, 14513 Teltow, Germany; skadi.lau@hzg.de (S.L.); manfred.gossen@hzg.de (M.G.)
2 Institute of Chemistry, University of Potsdam, 14476 Potsdam, Germany
* Correspondence: andreas.lendlein@hzg.de (A.L.); friedrich.jung@hzg.de (F.J.)

Abstract: Although cardiovascular devices are mostly implanted in arteries or to replace arteries, in vitro studies on implant endothelialization are commonly performed with human umbilical cord-derived venous endothelial cells (HUVEC). In light of considerable differences, both morphologically and functionally, between arterial and venous endothelial cells, we here compare HUVEC and human umbilical cord-derived arterial endothelial cells (HUAEC) regarding their equivalence as an endothelial cell in vitro model for cardiovascular research. No differences were found in either for the tested parameters. The metabolic activity and lactate dehydrogenase, an indicator for the membrane integrity, slightly decreased over seven days of cultivation upon normalization to the cell number. The amount of secreted nitrite and nitrate, as well as prostacyclin per cell, also decreased slightly over time. Thromboxane B2 was secreted in constant amounts per cell at all time points. The Von Willebrand factor remained mainly intracellularly up to seven days of cultivation. In contrast, collagen and laminin were secreted into the extracellular space with increasing cell density. Based on these results one might argue that both cell types are equally suited for cardiovascular research. However, future studies should investigate further cell functionalities, and whether arterial endothelial cells from implantation-relevant areas, such as coronary arteries in the heart, are superior to umbilical cord-derived endothelial cells.

Keywords: human umbilical cord-derived endothelial cells; cardiovascular research; cardiovascular implants; artery endothelial cell compatibility testing

1. Introduction

Cardiovascular diseases, such as coronary artery disease affecting the heart, stroke affecting the brain, peripheral artery disease affecting the extremities, and aortic disease affecting all inner organs, represent the number one cause of death worldwide [1]. To restore blood flow in constricted vessels, cardiovascular devices such as stents or vascular grafts are often implanted. Hereby, mostly arteries are affected [2]. Since the coverage with endothelial cells (EC), which form a confluent monolayer on the inner side of all blood vessels, plays a critical role in the success of implants, much research has been conducted on the performance of this cell type on implant surfaces. Human umbilical vein endothelial cells (HUVEC) have represented the most common EC type used for in vitro endothelial cell research since 1973, due to the simple, quick, and inexpensive isolation process [3]. Results of HUVEC-based studies are often assumed to be transferrable to other EC types, such as arterial EC from different regions of the human body. However, a growing body of evidence shows that the endothelium is highly heterogeneous depending on the vascular bed, and that arterial EC differ from venous EC. As early as 1988, Wagner et al. showed that EC from bovine aortas differ from those of the venous circulation in terms of size, thickness, proliferation, and protein synthesis [4]. Arterial EC are typically thicker, and exhibit a rather long and ellipsoidal morphology compared to shorter and wider venous endothelial
cells. This difference is probably due to different shear stress levels, which are higher in arteries than in veins (reviewed in [5,6]). Moreover, the molecular gene signature differs, as was shown by the identification of eight transcription factors that co-determine the arterial fingerprint in arterial EC compared to venous EC [7]. Today, two main identification markers, namely EphrinB2 for arterial EC, and EphB4 for venous EC, have been established [8]. Considering these differences it seems likely that arterial and venous EC also differ in their functions. It is known that the control of vascular tone is mainly attributed to arterioles. In contrast, post-capillary venules are the primary site of permeability and leukocyte trafficking during inflammation (reviewed in [5]). The formation of new blood vessels from existing ones, referred to as angiogenesis, occurs in both arteries and veins. Interestingly, this process is equally supported by vascular endothelial growth factor, but differentially inhibited by endogenous opioid growth factor [9].

Apart from these differences between venous and arterial EC, umbilical cord-derived EC represent a special case compared to EC located in the systemic circulation. In the latter, it is the function of arteries to transport oxygen- and nutrient-rich blood to organs, while veins deport oxygen- and nutrient-poor blood away from organs. In the umbilical cord, this situation is reversed. The umbilical cord-derived vein provides the fetus with oxygen and nutrients, while waste products are transported back to the mother through the arteries [10]. This raises the question of whether HUVEC could be considered as arterial EC and vice versa. A DNA microarray-based study comparing EC from various sources pointed against this hypothesis by showing that HUVEC cluster with EC from other veins, while HUAEC cluster with EC from other arteries in the systemic circulation [11]. Nevertheless, we asked ourselves whether HUVEC are actually a suitable cell type in the context of cardiovascular device testing, which is predominantly implanted in arteries or used to replace arteries. Instead, arterial cells from regions of the body that are targets of cardiovascular therapies, such as coronary arteries in the heart, might be superior to venous EC. However, EC from these sources are rarely available. In contrast, umbilical cords, each of which normally contains one vein and two arteries, are medical waste, and thus available in high numbers. A few recent studies chose human umbilical arterial endothelial cells (HUAEC), possibly anticipating that study results obtained with these cells are closer to arterial application areas than those obtained with HUVEC [12,13]. However, we are not aware of any study that has systematically analyzed HUVEC and HUAEC side-by-side for the characteristic properties of endothelial cells necessary for cardiovascular therapies. Endothelialization of implants requires the adhesion and proliferation of viable EC. Moreover, adherent EC need to be functional, with regard to the secretion of vasoactive substances such as nitric oxide, prostacyclin, and thromboxane, in order to control vasomotor tone, and to prevent platelet adhesion. In addition, the production of extracellular matrix proteins is important for enabling remodeling processes. Thus, it is the aim of the present study to compare HUVEC and HUAEC regarding cell viability, cell density, metabolic activity, membrane integrity, actin fiber patterns, secretion of vasoactive substances, and the production of von Willebrand factor, as well as of extracellular matrix proteins (collagens and laminin).

2. Results

HUVEC are the most widely used cell type for in vitro endothelial cell research. The present study was conducted to explore the use of HUAEC as a potential alternative to HUVEC. For this, both cell types were cultivated for seven days and analyzed regarding several endothelial cell-specific properties. Phase contrast images revealed that the cell morphology of both cell types was similar (Figure 1). While few of the EC showed the characteristic morphology at day 2 of cultivation, rather displaying a roundish to elongated shape, they phenotypically shifted towards a typical cobblestone-like pattern with increasing cell density at day 4 and 7. Analysis of cell viability (FDA/PI-assay) revealed a moderate increase over time in the fraction of dead cells, as indicated by the presence of mainly viable/green cells and few dead/red cells (Figure 2A). At day 2, 99.9% ± 0.4% (HUVEC), and 99.8% ± 0.7% (HUAEC) of the cells were viable. At day 4, cell viability de-
creased only marginally to 99.7% ± 0.4% (HUVEC), and 97.9% ± 2.6% (HUAEC). A more substantial decrease of cell viability was detected at day 7, however, in a comparable manner for both cell types. Among HUVEC, 94.9% ± 7.8% of cells were viable, while among HUAEC, 95.0% ± 6.4% were viable (Figure 2B). No statistical differences were found between HUVEC and HUAEC, with regard to cell viability and also cell density, which increased with both HUVEC and HUAEC in a similar fashion over time (Figure 2C).

The MTS assay is based on the enzymatic reduction of a yellow tetrazolium salt into red formazan by NAD(P)H-dependent dehydrogenases, a reaction that is restricted to metabolically active, viable cells. Thus, this method assesses both metabolic activity and cell viability. Moreover, it is often used to determine proliferation, since the generation of formazan increases with increasing cell numbers. Here, the metabolic activity was normalized to the number of vital adherent HUVEC and HUAEC to compensate for cell count-dependent differences. While absolute numbers per well increased over time, upon normalization a slight reduction in signal per cell was observed. No statistically significant differences were detected between the two cell types at any time point (Figure 3A). The same was true for the membrane integrity, as assessed by the release of lactate dehydrogenase (LDH). While absolute numbers per well increased up to day 7, though not as much as with the mitochondrial activity, data normalization resulted in a slight decrease of the LDH release over time. However, no statistically significant differences were found between HUVEC and HUAEC (Figure 3B).
Figure 2. Endothelial cell viability and density. Human umbilical cord-derived endothelial cells from veins (HUVEC) or arteries (HUAEC) were seeded at a density of 15,000 cells/well at day 0, and cultivated for 2, 4, and 7 days. Cell viability staining detected living (green) and dead (red) cells (A). Quantification of vital cells showed that only a few cells died over time (B). The cell density, expressed as the number of vital adherent cells per mm$^2$, increased over time (C). Fluorescent images were taken at 10-fold primary magnification. Scale bar represents 100 µm, and 50 µm in the magnified image sections in the upper right corner of each image. Squares with dashed lines indicate the image region that was magnified. Straight black lines indicate $p \leq 0.0099$.

Figure 3. Metabolic activity (A) and membrane integrity (B) of endothelial cells. Human umbilical cord-derived endothelial cells from veins (HUVEC) or arteries (HUAEC) were seeded at a density of 15,000 cells/well at day 0 and cultivated for 2, 4, and 7 days. The metabolic activity and membrane integrity were normalized to the number of vital adherent cells per mm$^2$ leading to decreasing values over time. Straight black lines indicate $p \leq 0.0058$. 
The production of vasoactive substances is a characteristic property of functional endothelial cells. The total amount of secreted nitrite and nitrate per well, two stable metabolites of nitric oxide, remained constant over the seven days of cultivation. Upon normalization to the cell number, which increased over time, the amount of nitrite and nitrate per cell decreased. The absolute amounts of prostacyclin increased up to day 7, though only marginally. Consequently, the amount of secreted prostacyclin per cell slightly decreased over time. However, no significant differences were observed between HUVEC and HUAEC except for the prostacyclin production at day 2, which was slightly reduced in the case of HUAEC compared to HUVEC (Figure 4A,B). In contrast, the total amount of thromboxane B2 increased over time, resulting in constant values upon normalization to the cell number (Figure 4C). At day 2, HUAEC did not produce any thromboxane B2. At day 4 and day 7, no differences were visible between HUVEC and HUAEC.

Finally, the presence of actin fibers, vWF, and extracellular matrix molecules, collagen and laminin, was evaluated by antibody-staining. In general, no differences were detected between HUVEC and HUAEC. Actin fibers were observed at all time points, however, the localization in the cells slightly differed depending on the time point. For example, at day 2, actin fibers in most cells pervaded the whole cell body. This was also observed at day 4 and 7, however, at these time points, an increasing number of cells also showed cortical actin filaments and an actin fiber-free cytoplasmic area (Figure 5, white arrows). vWF was mainly present intracellularly at all time points, but some vWF fibers were also detected in the extracellular space at day 4 and 7 (Figure 6, white arrows). The production of collagen and laminin increased over the 7 days of cultivation. Traces of collagen were visible at day 2 in the form of small little dots, which were most likely inside the cells. At day 4, some short fibers were observed, and at day 7 large networks of collagen fibers were present throughout the cell layer, indicating the secretion of collagen into the environment (Figure 7). Similarly, laminin was detected within the cells at day 2 and day 4. With increasing cell density, thin laminin strands connecting two or more cells were observed. At day 7, a dense laminin-based fleece seemed to cover the substrate underneath the cells (Figure 8).
Figure 5. Expression of actin fibers by endothelial cells. Human umbilical cord-derived endothelial cells from veins (HUVEC) or arteries (HUAEC) were seeded at a density of 15,000 cells/well at day 0 and cultivated for 2, 4, and 7 days. While most of the cells exhibited actin fibers throughout the cell body at day 2, an increasing number of cells with pronounced cortical actin fibers were present at day 4 and 7 (indicated by white arrows). Fluorescent images were taken at 20-fold primary magnification. Scale bar represents 50 µm, and 25 µm in the magnified image sections in the upper right corner of each image. Squares with dashed lines indicate the image region that was magnified.

Figure 6. Expression of von Willebrand factor (vWF) by endothelial cells. Human umbilical cord-derived endothelial cells from veins (HUVEC) or arteries (HUAEC) were seeded at a density of 15,000 cells/well at day 0 and cultivated for 2, 4, and 7 days. Cells from both sources expressed vWF at all time points. At day 4 and 7, some extracellular vWF fibers were observed (white arrows). Fluorescent images were taken at 20-fold primary magnification. Scale bar represents 50 µm, and 25 µm in the magnified image sections in the upper right corner of each image. Squares with dashed lines indicate the image region that was magnified.
Figure 7. Expression of collagen I-V by endothelial cells. Human umbilical cord-derived endothelial cells from veins (HUVEC) or arteries (HUAEC) were seeded at a density of 15,000 cells/well at day 0 and cultivated for 2, 4, and 7 days. While only traces of collagen were detected at day 2, the expression increased with increasing cultivation time, leading to large networks of collagen fibers at day 7 with cells from both sources. Fluorescent images were taken at 20-fold primary magnification. Scale bar represents 50 µm, and 25 µm in the magnified image sections in the upper right corner of each image. Squares with dashed lines indicate the image region that was magnified.

Figure 8. Expression of laminin by endothelial cells. Human umbilical cord-derived endothelial cells from veins (HUVEC) or arteries (HUAEC) were seeded at a density of 15,000 cells/well at day 0, and cultivated for 2, 4, and 7 days. While laminin was only intracellularly present at day 2, it was secreted into the extracellular space with increasing cultivation time, leading to a wide fleece-like network at day 7. Fluorescent images were taken at 20-fold primary magnification. Scale bar represents 50 µm, and 25 µm in the magnified image sections in the upper right corner of each image. Squares with dashed lines indicate the image region that was magnified.
3. Discussion

Cardiovascular implants are most frequently implanted to restore arterial functions. However, most studies have been performed with venous EC. To evaluate whether differences between umbilical cord-derived venous and arterial EC exist regarding selected properties necessary for cardiovascular implants, the present study compared cells from both sources side-by-side. The major finding is that no differences in either of the tested parameters were found between EC from both sources.

Proliferation of cells from both sources was comparable over the seven days of cultivation. This is in agreement with a study by Rosa et al., who compared iPSC-derived EC, HUVEC, and HUAEC on three different substrates [14]. However, the general opinion is that EC proliferation in veins is higher than in arteries [15]. The use of specific proliferation markers, such as Ki67, and assays based on DNA replication, such as the BrdU assay, might be useful in future studies to investigate this issue in detail. On the other hand, there is increasing evidence for the heterogeneity of the endothelium depending on the vascular bed, the developmental stage, and the microenvironment. In blood, different types of endothelial progenitor cells exist, which can be differentiated by their high proliferative capacity [16]. These progenitors were also found in the wall of mature arteries and veins, explaining why HUVEC and HUAEC can be cultivated to a comparable number of population doublings like progenitor cells [17]. Since the proliferation capacity of progenitor cells is greater than that of mature EC, HUVEC and HUAEC might have been overgrown by these progenitor cells resulting in similar proliferation behaviors. To investigate this issue, progenitor cells could be identified by their clonogenic potential in single cell colony forming assays. Moreover, cells could be analyzed regarding endothelial progenitor markers, such as CD34 or CD133, which should be absent in mature EC [18].

The metabolic activity differs between arterial, venous, microvascular, and lymphatic EC in terms of glucose and oxygen consumption, the amount of intracellular ATP levels and other parameters (reviewed in [19]). With regard to umbilical cord-derived EC, the metabolism of HUVEC was mostly studied, while HUAEC were largely neglected. For example, Lorenz et al. found that serum starvation and treatment with vascular endothelial growth factor induced higher intracellular ATP levels in female HUVEC than in male cells, indicating an energetic advantage for female cells over male cells [20]. Another study revealed that the metabolic activity increased with increasing cultivation time as assessed by enzymes involved in glycolysis and the citric acid cycle [21]. One study reported both HUVEC and HUAEC to have a similar glycolytic flux (reviewed in [22,23]). This is in agreement with the present study, which also detected a similar metabolic activity by MTS assay, a measure of the glycolytic activity of cells.

A confluent monolayer of intact EC in the blood vessel lumen ensures a selective permeability for molecules and cells. An impaired membrane integrity, e.g., measured by an increased release of lactate dehydrogenase, would reduce barrier function. For example, necrotic and late apoptotic cells exhibit a compromised membrane integrity compared to healthy cells [24]. Likewise, inflammatory molecules, such as tumor necrosis factor α or hyperglycemic conditions, as present in diabetes, can also change the integrity [25,26]. Thus, it is not surprising that, in the present study, low passage HUVEC and HUAEC cultivated without any disturbing factors show a comparably intact membrane integrity. Future studies using fluorescent dextran diffusion or staining of inter-endothelial junctions might reveal additional insights regarding the endothelial barrier function of venous and arterial EC.

The secretion of vasoactive substances by EC has been analyzed in multiple studies. Nitric oxide (NO) and prostacyclin are important vasodilators, leading to the relaxation of smooth muscle cells and a reduction of blood pressure. In contrast, thromboxane A2 (here the more stable variant thromboxane B2 was measured) induces vasoconstriction and an increase of blood pressure. Several studies have investigated these parameters in vitro and in vivo, with different results. Fukaya et al. found that EC of canine arteries released more NO than EC of veins in response to acetylcholine and flow [27]. In contrast, cultured
EC from porcine femoral artery and vein showed a comparable production of NO after stimulation with lipopolysaccharide. However, prostacyclin secretion was lower in venous cells compared to arterial cells [28]. An early study found that bovine arterial and venous EC produce similar amounts of prostacyclin and NO [29]. With regard to thromboxane, and in the absence of stimulators, it was shown that HUVEC, which are macrovascular cells, produce less thromboxane compared to microvascular EC from the placenta or foreskin. On the other hand, no differences in the prostacyclin production were found [30]. In the present study, the secretion of all three tested substances was similar for HUVEC and HUAEC. Considering the different results of the aforementioned studies, none of which compared human macrovascular EC, it can be speculated that the production of vasoactive molecules is highly dependent on the species, the classification as macro- or microvascular EC, and most likely also on culture conditions. Moreover, one has to keep in mind that a comparison of different studies is complicated by the use of different stimulators, which differently regulate the production of vasoactive substances.

Actin fibers, as part of the cytoskeleton, were observed in EC from both sources at all time points. While these fibers pervaded the whole cell body of most cells at day 2, they shifted towards the outer cell boundary at day 4 and day 7. This indicated the formation of a functionally confluent endothelial monolayer, important for mediating anti-thrombogenic actions [31]. The von Willebrand factor (vWF) is a key player in hemostasis, stored in Weibel–Palade bodies in EC, and released both constitutively at low concentrations, and at events of inflammation in high amounts (reviewed in [32,33]). For example, EC activation by high concentrations of acrolein, a metabolite of the anti-cancer drug cyclophosphamide, induces a complete loss of vWF in HUVEC [34]. While cultivation of EC under shear stress stimulates the elongation of secreted vWF molecules, few vWF fibers are released under static conditions [35]. In the present study, vWF largely remained intracellularly in EC from both sources, with few fibers in the extracellular space at all time points, indicating that no cell activation took place.

Collagen type IV, and laminin 411 and 511 (isotypes 8 and 10) are central components of the endothelial basal lamina, a specialized part of the extracellular matrix (reviewed in [36]). Surprisingly little is known about the spatial and temporal synthesis of these proteins in EC cultured in vitro. Kusuma et al. compared the production and release of collagen type I and IV, as well as laminin (isotype not specified), by endothelial progenitor cells and mature EC, such as HUVEC and HUAEC cultivated at three different oxygen concentrations (1% (v/v), 5% (v/v), and 21% (v/v) O₂), and at three different days of cultivation (1, 4, and 7 days). At 21% (v/v) O₂, only endothelial progenitor cells were able to produce collagen type IV at all time points. All three cell types produced laminin, which remained intracellularly in mature EC, but formed a network of fibers in the case of progenitor cells. Collagen type I was not detected. At 1% and 5% (v/v) O₂, all three EC types deposited a fibrous mesh of collagen type IV and laminin in the extracellular space. Collagen type I was yet again not detected [37]. The present study, using a pan-specific collagen antibody, found that the assembly of a fibrous collagen network started at day 4, and was fully developed at day 7 in cultures of both HUVEC and HUAEC cultivated at 21% (v/v) O₂. The same was true for laminin (isotype also not specified), which was increasingly secreted into the extracellular space with increasing cultivation time. In a previous study of our group, comparing arterial EC from different donors, collagen was also secreted at 21% (v/v) O₂ either at day 4 or day 7, depending on the individual donor. However, laminin, which was detected with the same antibody as used in the present study, remained intracellularly in cells from all donors [38]. Thus, the synthesis and especially the secretion of ECM molecules may not be exclusively oxygen-dependent, but also donor-dependent.

4. Materials and Methods

4.1. Study Design

Human umbilical vein endothelial cells (HUVEC) and human umbilical artery endothelial cells (HUAEC) were cultivated for 2 days, 4 days, and 7 days prior to the analysis
of cell viability, cell density, metabolic activity, membrane integrity, secretion of vasoactive substances (nitric oxide, prostacyclin, and thromboxane B2), and expression of filamentous actin fibers and von Willebrand factor, as well as extracellular matrix proteins, such as collagen and laminin. In total, three independent experiments were performed with 9 to 36 technical replicates, depending on the assay.

4.2. Cell Culture

Pooled HUVEC (from 3 to 6 individual donors, Lonza, Cologne, Germany) and HUAEC (from 250 individual donors, PeloBiotech GmbH, Planegg, Germany) were cultivated in EGM-2 Bullet Kit containing endothelial cell culture medium supplemented with 2% (v/v) fetal bovine serum, vascular endothelial growth factor, basic fibroblast growth factor, human epithelial growth factor, insulin-like growth factor-1, hydrocortisone, heparin, ascorbic acid, gentamycin, and amphotericin B (Lonza) in a standard humidified incubator at 37 °C with 5% (v/v) CO₂. Cells of passage 5 were seeded in 4-well PCA chamber slides (Sarstedt, Nürnberg, Germany) at a cell density of 15,000 cells/well with 1 mL medium per well, and cultivated for up to 7 days. Medium was exchanged at day 2 and day 4 of cultivation.

4.3. Cell Viability

Cell viability was assessed by fluorescein diacetate (FDA, 12.5 µg·mL⁻¹, Invitrogen, Darmstadt, Germany) to stain viable cells green, and propidium iodide (PI, 1 µg·mL⁻¹, Sigma-Aldrich, Taufkirchen, Germany) to stain dead cells red. For this, both FDA and PI were simultaneously added to the cell culture medium and images of stained cells were immediately taken in a 10-fold primary magnification (Axio Vert.A1, Zeiss, Jena, Germany). Numbers of viable and dead cells were counted using Fiji is just imageJ (version 1.48c) [39] and expressed in percent of the total cell number. Moreover, the cell density of viable adherent cells was normalized to the growth area, and expressed as the number of vital adherent cells per mm² (n = 36; three independent experiments with 12 images per experiment, taken from four different wells).

4.4. Metabolic Activity

The metabolic activity of cells was assessed using a MTS cell Titer 96 Aqueous Non-radioactive Cell Proliferation Assay (MTS assay, Promega, Mannheim, Germany) according to the manufacturer’s instructions. Briefly, 100 µL of MTS-mixture was added to 500 µL cell culture supernatant in a 24-well plate (Th. Geyer, Berlin, Germany). After 3 h of incubation at 37 °C, the absorbance was measured at 492 nm using a photometer (Tecan infinite M200 pro, Crailsheim, Germany). The metabolic activity was normalized to the number of vital adherent cells per mm² (n = 9; three independent experiments measured in triplicates).

4.5. Cell Membrane Integrity

The cell membrane integrity was measured using a LDH Cytotoxicity Assay Kit II (Roche, Grenzach, Germany) according to the manufacturer’s instructions. Briefly, 10 µL of cell culture supernatant was added to 100 µL of LDH reaction mix, and incubated for 30 min at room temperature in the dark. The absorbance was measured at 450 nm (reference wavelength: 650 nm) using a photometer (Tecan infinite M200 pro). The cell membrane integrity was normalized to the number of vital adherent cells per mm² (n = 36; three independent experiments with three different wells per experiment, measured in four technical replicates).

4.6. Ultrafiltration and Lyophilization of Cell Culture Supernatants

To quantify the amount of vasoactive substances produced by HUVEC and HUAEC at day 2, day 4, and day 7 of cultivation, cell culture supernatants were collected at each time point. Since fetal bovine serum (FBS) can interfere with enzyme linked immunosorbent
assays, it was removed from supernatants by ultrafiltration. For this, ultracentrifugation
tubes (Amicon, Merck KGaA, Darmstadt, Germany) with 10 kDa filter membranes were
wetted with ultra-pure water (Cayman Chemicals, Hamburg, Germany), and subsequently
filled with cell culture supernatant. Tubes were centrifuged for 20 min at $4000 \times g$ and
room temperature. Finally, the FBS-free supernatants were stored at $-20^\circ C$. Since the
concentration of vasoactive substances in cell culture medium is relatively low, and often
close to the detection limit, samples were lyophilized to increase the concentration of these
substances, and allow their measurement in a reliable range of the standard curve. For this,
frozen samples were lyophilized using an ALPHA 1-4 LD plus (Christ, Osterode, Germany)
for four days. Finally, lyophilized samples were stored at $-20^\circ C$ until quantification.

4.7. Quantification of Secreted Vasoactive Substances

4.7.1. Nitric Oxide

Nitric oxide production by cells was indirectly measured by quantification of the more
stable metabolites of nitric oxide, nitrate, and nitrite, using a commercial kit (Total nitric
oxide and nitrate/nitrite Kit, R&D Systems, Wiesbaden, Germany) according to the manu-
facturer’s instructions. In the first step, the amount of endogenous nitrite was measured. In
a second step, the amount of total nitrite, generated after enzymatic conversion of nitrate
into nitrite by nitrate reductase, was colorimetrically detected as an azo dye product of the
Griess reaction. To calculate the amount of nitrate, the endogenous nitrite was subtracted
from the total nitrite. Technically, 50 $\mu$L cell culture supernatant was used per well, and
measurements were performed in triplicates. Absorbance was recorded at 540 nm (refer-
cence wavelength: 690 nm) using a photometer (Tecan infinite M200 pro). All concentrations
were calculated based on a standard curve and normalized to the number of vital adherent
cells per mm$^2$ ($n = 9$; three independent experiments, measured in triplicates).

4.7.2. Prostacyclin and Thromboxane B2

Prostacyclin and thromboxane B2 secretion was quantified using two different com-
petitive enzyme immunoassays (6-keto Prostaglandin $F_{1\alpha}$ ELISA Kit, and Thromboxane
B2 ELISA Kit, Cayman Chemical, Hamburg, Germany) according to the manufacturer’s
instructions. Briefly, 50 $\mu$L cell culture supernatant was used per well and measurements
were performed in triplicates. Absorbance was recorded at 410 nm using a photometer
(Tecan infinite M200 pro). Prostacyclin and thromboxane B2 concentrations were calculated
based on a standard curve, and normalized to the number of vital adherent cells per mm$^2$
($n = 9$; three independent experiments measured in triplicates).

4.8. Fluorescence Staining of Actin Fibers, Von Willebrand Factor, Collagen and Laminin

To visualize filamentous actin fibers, von Willebrand factor, collagen, and laminin,
an immunocytological staining was performed. For this, cells were fixed with 4% ($w/v$)
paraformaldehyde (Sigma-Aldrich, Taufkirchen, Germany) for 30 min, permeabilized using
0.5% ($v/v$) Triton-X-100 for 10 min (Sigma-Aldrich, Taufkirchen, Germany), and unspe-
cific binding sites were blocked with 5% ($w/v$) bovine serum albumin (Roth, Karlsruhe,
Germany) for 20 min at room temperature. As primary antibodies, rabbit anti-human
von Willebrand factor (Sigma-Aldrich, F3520, 1:200), rabbit anti-human collagen type I-V
(Abcam, Cambridge, United Kingdom, ab36064, 1:250), and mouse anti-human laminin
(Novus Biologicals, Wiesbaden Nordenstadt, Germany, NB600-883, 1:250) were incubated
for 1 h at room temperature. After three washing steps with phosphate buffered saline
(Thermo Fisher Scientific, Berlin, Germany) cells were incubated with the secondary anti-
bodies, donkey anti-rabbit IgG conjugated to Alexa Fluor 488 (Thermo Fisher Scientific,
A21206, 1:500, for vWF), donkey anti-rabbit IgG conjugated to DyLight 550 (Thermo Fisher
Scientific, SA5-10039, 1:500, for collagen I-V), and donkey anti-mouse IgG conjugated to
Alexa Fluor 488 (Thermo Fisher Scientific, A31570, 1:400, for laminin) for 1 h at room temperature in the dark. Finally, cells were washed and covered with ROTI®Mount FluorCare as mounting medium, containing 4′,6-diamidino-2-phenylindole (DAPI, Roth, Karlsruhe, Germany) to counterstain cell nuclei. For qualitatively analysis, images were taken in 20-fold primary magnification using a confocal laser scanning microscope (DMi8, Leica, Wetzlar, Germany) (n = 18; three independent experiments, where 2 images were taken per well from a total of three wells per experiment).

4.9. Statistics
Statistical analyses were performed using Graphpad Prism 6 (Graphpad Software, San Diego, CA, USA). Gaussian distribution of the data was tested using the d’Agostino–Pearson omnibus normality test. Data are reported as arithmetic mean ± standard deviation. Comparisons between multiple groups were performed by Kruskal–Wallis test, with Dunn’s posttest for non-parametric data. Differences were considered significant at p < 0.05.

5. Conclusions
The present study did not detect any notable differences between HUVEC and HUAEC regarding selected EC-specific properties necessary for the successful endothelialization of cardiovascular implants, including proliferation, and secretion of vasoactive substances and extracellular matrix proteins. Consequently, EC from both sources can be equally used for in vitro endothelial cell research, despite the fact that cardiovascular implants are mainly applied in the arterial system. This means that study results on implant endothelialization obtained with HUVEC most likely reflect the behavior of arterial EC. In light of potentially applying these findings in preclinical studies, and (while using clinical-grade cell sources) in the future also in clinical applications, it remains to be investigated whether arterial EC from areas that are targets for cardiovascular implants, such as coronary arteries, are superior to umbilical cord-derived blood vessels with regard to the in vitro evaluation of cardiovascular implant materials.

Author Contributions: Conceptualization, F.J.; Formal analysis, S.L.; Investigation, S.L.; Writing—Original Draft, S.L.; Writing—Review & Editing, M.G., F.J., and A.L., Visualization, S.L.; Supervision, M.G. and F.J.; Project administration, A.L.; Funding acquisition, A.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was financially supported by the Helmholtz Association through programme-oriented funding.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: Angelika Ritschel and Luisa Grünberg are acknowledged for technical assistance in the performance of all experiments.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. WHO. Cardiovascular Diseases (CVDs). 2017. Available online: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 15 January 2021).
2. Chlupáč, J.; Filová, E.; Bacáková, L. Blood vessel replacement: 50 years of development and tissue engineering paradigms in vascular surgery. Physiol. Res. 2009, 58 (Suppl. S2), S119–S139. [PubMed]
3. Jaffe, E.A.; Nachman, R.L.; Becker, C.G.; Minick, C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Investig. 1973, 52, 2745–2756. [CrossRef] [PubMed]
4. Wagner, W.H.; Henderson, R.M.; Hicks, H.E.; Banes, A.J.; Johnson, G. Differences in morphology, growth rate, and protein synthesis between cultured arterial and venous endothelial cells. J. Vasc. Surg. 1988, 8, 509–519. [CrossRef]
5. dela Paz, N.G.; D’Amore, P.A. Arterial versus venous endothelial cells. Cell Tissue Res. 2009, 335, 5–16. [CrossRef] [PubMed]
6. Aird, W.C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. *Circ. Res.* 2007, 100, 158–173. [CrossRef]

7. Aranguren, X.; Agirre, X.; Beeren, M.; Coppolio, G.; Uriz, M.; Vandersmissen, I.; Benkheil, M.; Panadero, J.; Aguado, N.; Pascual-Montano, A.; et al. Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. *Blood* 2013, 122, 3982–3992. [CrossRef]

8. Icli, B.; Feinberg, M.W. Plasticity of Arterial and Venous Endothelial Cell Identity. *Circ. Res.* 2016, 119, 574–576. [CrossRef]

9. Blebea, J.; Vu, J.-H.; Assadnia, S.; McLaughlin, P.J.; Atmip, R.G.; Zagon, I.S. Differential effects of vascular growth factors on arterial and venous angiogenesis. *J. Vasc. Surg.* 2002, 35, 532–538. [CrossRef]

10. Spurway, J.; Logan, P.; Pak, S. The development, structure and blood flow within the umbilical cord with particular reference to the venous system. *Australas. J. Ultrasound Med.* 2012, 15, 97–102. [CrossRef]

11. Chi, J.-T.; Chang, H.Y.; Haraldsen, G.; Jahnson, F.L.; Troyanskaya, O.G.; Chang, D.S.; Wang, Z.; Rockson, S.G.; van de Rijn, M.; Botstein, D.; et al. Endothelial cell diversity revealed by global expression profiling. *Proc. Natl. Acad. Sci. USA* 2003, 100, 10623. [CrossRef]

12. Wolf, F.; Gonzalez, D.M.R.; Steinegger, U.; Obdenbusch, M.; Herfs, W.; Brecher, C.; Jockenhoevel, S.; Mela, P.; Schmitz-Rode, T. VascuTrainer: A Mobile and Disposable Bioreactor System for the Conditioning of Tissue-Engineered Vascular Grafts. *Ann. Biomed. Eng.* 2018, 46, 616–626. [CrossRef] [PubMed]

13. Li, H.L.; Pei, H.Y.; Nie, J.Q.; Qu, M.Y.; Fan, Z.; Jia, Y.L.; He, L.J.; Nan, X.; Yue, W.; Pei, X.T. Integration-free reprogramming of human umbilical arterial endothelial cells into induced pluripotent stem cells iHSTMi001-A. *Stem Cell Res.* 2018, 31, 231–234. [CrossRef] [PubMed]

14. Rosa, S.; Praça, C.; Pitreza, P.R.; Gouveia, P.J.; Aranguren, X.L.; Ricotti, L.; Ferreira, L.S. Functional characterization of iPSC-derived arterial- and venous-like endothelial cells. *Sci. Rep.* 2019, 9, 3826. [CrossRef]

15. Rocha, S.F.; Adams, R.H. Molecular differentiation and specialization of vascular beds. *Angiogenesis* 2009, 12, 139–147. [CrossRef] [PubMed]

16. Ingram, D.A.; Mead, L.E.; Tanaka, H.; Meade, V.; Fenoglio, A.; Mortell, K.; Pollok, K.; Ferkowicz, M.J.; Gilley, D.; Yoder, M.C. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. *Blood* 2004, 104, 2752–2760. [CrossRef]

17. Ingram, D.A.; Mead, L.E.; Moore, D.B.; Woodard, W.; Fenoglio, A.; Yoder, M.C. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. *Blood* 2005, 105, 2783–2786. [CrossRef]

18. Steurer, M.; Kern, J.; Zitt, M.; Amberger, A.; Bauer, M.; Gastl, G.; Untergasser, G.; Gunsilius, E. Quantification of circulating endothelial and progenitor cells: Comparison of quantitative PCR and four-channel flow cytometry. *BMC Res. Notes* 2008, 1, 71. [CrossRef]

19. Eelen, G.; de Zeewu, P.; Simons, M.; Carmeliet, P. Endothelial cell metabolism in normal and diseased vasculature. *Circ. Res.* 2015, 116, 1231–1244. [CrossRef]

20. Lorenz, M.; Blaschke, B.; Benn, A.; Hammer, E.; Witt, E.; Kirwan, J.; Fritsche-Guenther, R.; Gloaguen, Y.; Bartsch, C.; Vietzke, A.; et al. Sex-specific metabolic and functional differences in human umbilical vein endothelial cells from twin pairs. *Atherosclerosis* 2019, 291, 99–106. [CrossRef]

21. Peters, K.; Kamp, G.; Berz, A.; Unger, R.E.; Barth, S.; Salamon, A.; Rychly, J.; Kirkpatrick, C.J. Changes in human endothelial cell energy metabolic capacities during in vitro cultivation. The role of “aerobic glycolysis” and proliferation. *Cell. Physiol. Biochem.* 2009, 24, 483–492. [CrossRef]

22. Eelen, G.; de Zeewu, P.; Treps, L.; Harjes, U.; Wong, B.W.; Carmeliet, P. Endothelial Cell Metabolism. *Physiol. Rev.* 2018, 98, 3–58. [CrossRef] [PubMed]

23. De Bock, K.; Georgiadou, M.; Schoors, S.; Ukimura, J.; Wensing, I.; Benkheil, M.; Panadero, J.; Aguado, N.; Pascual-Montano, A.; et al. Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. *Blood* 2013, 122, 3982–3992. [CrossRef]

24. Senthil, K.K.J.; Gokila, V.M.; Wang, S.-Y. Activation of Nrf2-mediated anti-oxidant genes by antrodin C prevents hyperglycemia-induced senescence and apoptosis in human endothelial cells. *Oncotarget* 2017, 8, 96568–96587. [CrossRef]

25. Fukaya, Y.; Ohhashi, T. Acetylcholine- and flow-induced production and release of nitric oxide in arterial and venous endothelial cells. *Am. J. Physiol. Heart Circ. Physiol.* 1996, 270, H99–H106. [CrossRef]

26. Geenen, I.L.A.; Molin, D.G.M.; van den Akker, N.M.S.; Jeukens, F.; Spronk, H.M.; Schurink, G.W.H.; Post, M.J. Endothelial cells (ECs) for vascular tissue engineering: Venous ECs are less thrombogenic than arterial ECs. *J. Tissue Eng. Regener. Med.* 2015, 9, 564–576. [CrossRef]

27. D’Orleans-Juste, P.; Mitchell, J.A.; Wood, E.G.; Hecker, M.; Vane, J.R. Comparison of the release of vasoactive factors from venous and arterial bovine cultured endothelial cells. *Can. J. Physiol. Pharmacol.* 1992, 70, 687–694. [CrossRef]

28. Lang, I.; Pabst, M.A.; Hiden, U.; Blaschitz, A.; Dohr, G.; Hahn, T.; Desoye, G. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. *Eur. J. Cell Biol.* 2003, 82, 163–173. [CrossRef] [PubMed]
31. Kruger-Genge, A.; Fuhrmann, R.; Jung, F.; Franke, R.P. Morphology of primary human venous endothelial cell cultures before and after culture medium exchange. *Clin. Hemorheol. Microcirc.* 2015, 61, 151–156. [CrossRef] [PubMed]

32. Nightingale, T.; Cutler, D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. *J. Thromb. Haemost.* 2013, 11 (Suppl. S1), 192–201. [CrossRef] [PubMed]

33. Rusu, L.; Minshall, R. Endothelial Cell von Willebrand Factor Secretion in Health and Cardiovascular Disease. In *Endothelial Dysfunction—Old Concepts and New Challenges*; IntechOpen Limited: London, UK, 2018.

34. Lau, S.; Rangarajan, R.; Philidet, C.; Kruger-Genge, A.; Braune, S.; Kammerer, S.; Kupper, J.H.; Lendlein, A.; Jung, F. Effects of acrolein in comparison to its prodrug cyclophosphamide on human primary endothelial cells in vitro. *Toxicol. In Vitro* 2020, 62, 104685. [CrossRef] [PubMed]

35. Cho, J.-S.; Ouriel, K. Differential Thrombogenicity of Artery and Vein: The Role of von Willebrand Factor. *Ann. Vasc. Surg.* 1995, 9, 60–70. [CrossRef]

36. Witjas, F.M.R.; van den Berg, B.M.; van den Berg, C.W.; Engelse, M.A.; Rabelink, T.J. Concise Review: The Endothelial Cell Extracellular Matrix Regulates Tissue Homeostasis and Repair. *Stem Cells Transl. Med.* 2019, 8, 375–382. [CrossRef] [PubMed]

37. Kusuma, S.; Zhao, S.; Gerecht, S. The extracellular matrix is a novel attribute of endothelial progenitors and of hypoxic mature endothelial cells. *FASEB J.* 2012, 26, 4925–4936. [CrossRef]

38. Lau, S.; Rangarajan, R.; Krüger-Genge, A.; Braune, S.; Küpper, J.H.; Lendlein, A.; Jung, F. Age-related morphology and function of human arterial endothelial cells. *Clin. Hemorheol. Microcirc.* 2020, 74, 93–107. [CrossRef]

39. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. *Nat. Methods* 2012, 9, 676–682. [CrossRef]